AUG 10, 2026 · PHASE 3 TRIAL
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
ClinicalTrials.gov
Phase 3 trial still recruiting with no results posted; registry record describes planned study design and endpoints only, not outcomes.
Reported
Primary endpointPercent change in body weight from Baseline…
Estimated enrollment3600
Treatment durationAt least 76 weeks